Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
The pathogenesis of leukemia is primarily attributed to chromosomal translocation and gene mutations. Genomic alterations such as deletion, duplication, insertion, inversion, and translocation disrupt the normal structure of the genome, leading to the formation of oncogenic fusion proteins. These fusion proteins play a pivotal role in driving the development of various types of leukemia. Furthermore, they serve as significant molecular targets for drug development. Alfa Cytology offers comprehensive research services focused on investigating the function, expression patterns, protein distribution, and subcellular localization of oncogenic proteins in leukemia. By utilizing these services, you can explore novel potential targets and expedite the process of drug discovery.
Translocations, deletions, and other nonrandom chromosomal abnormalities are pivotal in the pathogenesis of numerous types of leukemia. However, it is important to note that the functional impact of any gene involved in tumor formation is mediated through the protein it encodes. In the context of leukemia, a multitude of oncogenic proteins assume a significant role in cellular proliferation, differentiation, and survival. Common examples of such proteins in leukemia include BCR-ABL1, PML-RARA, MLL fusion protein, and FLT3. Consequently, targeting and eliminating these proteins have emerged as a promising therapeutic approach for leukemia. By disrupting the function of these oncogenic proteins, it is possible to impede the aberrant cellular processes that drive leukemogenesis and promote disease progression.
We employ immunological techniques to detect, quantify, and determine the localization of specific proteins in various samples. Our range of immunological methods includes Western blotting, Immunohistochemistry (IHC), and Immunofluorescence (IF). These techniques enable us to accurately assess the presence and expression levels of target proteins, providing valuable insights into their distribution and cellular localization within the sample.
Purification of Oncogenic Proteins in Leukemia
Our protein purification services aim to isolate target proteins from complex mixtures. We utilize various purification methods, including affinity chromatography, ion exchange chromatography, and gel filtration chromatography. These techniques enable the efficient separation and purification of oncogenic proteins in leukemia, allowing for downstream analysis and functional characterization.
Analysis of Proteins in Leukemia by Mass Spectrometry
We employ mass spectrometry for quantitative identification of proteins. This powerful technique provides insights into protein molecular weight, structural composition, and post-translational modifications. Our Mass spectrometry analysis enhances the understanding of how oncogenic proteins in leukemia function and aids in the identification of potential therapeutic targets.
Protein Structure Analysis in Leukemia
We offer advanced structural analysis methods, including X-ray crystallography, nuclear magnetic resonance (NMR), and electron microscopy (EM). These techniques allow for the visualization and characterization of oncogenic protein structures in leukemia, providing valuable insights into their mechanisms of action and facilitating structure-based drug design.
Protein Interaction Studies
Our comprehensive services encompass a variety of techniques, including yeast two-hybrid, immunoprecipitation, co-immunoprecipitation, and surface plasmon resonance. These methods enable us to investigate the intricate interactions between oncogenic proteins and other molecules. Through our services, we offer valuable insights into these interactions, aiding in the understanding of the underlying mechanisms driving leukemia.
Analysis of Proteins in Leukemia by High-throughput Proteomics
We use mass spectrometry and other technologies to systematically study leukemia carcinogenic proteins' composition, modification, and interaction at the cellular or tissue level, to reveal the function and regulatory mechanisms of leukemia carcinogenic proteins. Our testing processes include sample pretreatment, chromatographic separation, mass spectrometry, and data analysis.
Analysis of Proteins in Leukemia by Functional Genomics
By employing transcriptomics, proteomics, and other comprehensive approaches, we systematically study and analyze the functions of genes or proteins on a large scale. Through these investigations, we help to uncover the functional networks and regulatory mechanisms of oncogenic proteins in leukemia.
Verification of Proteins in Leukemia by Gene Knockout and Knockdown
Through tools such as CRISPR-Cas9, target genes are knocked out or knocked down in cells or organisms, and changes in protein function are observed to verify their mechanisms of action in physiological and disease processes.
Alfa Cytology provides techniques and methods for characterizing the structure and function of leukemic oncogenic proteins to verify the functions and interactions of leukemic oncogenic proteins, thereby providing insight into the role and regulatory mechanisms of leukemic oncogenic proteins in biological processes. If you would like to know more about our analysis services, please contact us.